Sentences with phrase «with erlotinib»

Niclosamide may work as therapeutic for familial adenomatosis polyposis (FAP) by disrupting the axin - GSK3 interaction and for colon cancer in synergizing with erlotinib [52,53].

Not exact matches

The drug erlotinib is prescribed to between 10 — 30 per cent of patients with non-small cell lung cancer, which accounts for 85 per cent of all lung cancer cases.

For example, epidermal growth factor (EGFR) mutations may result in sensitivity to drugs that are EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib, whereas individuals with the EGFR T790M mutation are more resistant to these drugs.

June - Koo Lee, M.D., of Seoul National University Hospital, Seoul, Republic of Korea, and colleagues performed a meta - analysis of randomized controlled trials that compared first - generation EGFR TKI (erlotinib and gefitinib) treatment with conventional chemotherapy in patients with advanced NSCLC without mutation of the EGFR gene.

He was part of a team that recognized that only about 10 % of patients with NSCLC responded to the small molecule erlotinib — those whose tumors harbored mutations in the gene encoding EGFR.

Angélica Nogueira - Rodrigues, MD, PhD, of the Brazilian National Cancer Insitute, and her colleagues designed a phase 2 clinical trial to test the potential of the EFGR inhibitor erlotinib combined with chemoradiation therapy in 36 women with cervical cancer.

Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients with NSCLC have a mutation in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib.

Also, there was no significant difference in overall survival with gemcitabine (13.6 months) compared with gemcitabine plus erlotinib (11.9 months).

In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine - based induction chemotherapy, and assessed the effect of erlotinib on survival.

Researchers and physicians have shown success treating EGFR lung cancer, for example with EGFR inhibitors gefitinib and erlotinib.

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.

[21] In the recently presented FLAURA study, in which osimertinib was used in untreated patients with advanced EGFR - mutant NSCLC, the HR for systemic disease control and CNS control similarly favored osimertinib over erlotinib or gefitinib, supporting the preclinical data that showed osimertinib's penetration across the BBB and providing support for using this agent in first - line management of EGFR - mutant patients with brain metastases.

[29] The Radiation Therapy Oncology Group study 0320 evaluated WBRT + stereotactic radiosurgery (SRS) + erlotinib and found significant grade 3 — 5 toxicity rates of 49 %, compared with a rate of 11 % for WBRT alone; the toxicities observed included cytopenias, rash, fatigue, and dehydration, among others.

The drug erlotinib is prescribed to between 10 - 30 per cent of patients with non-small cell lung cancer, which accounts for 85 per cent of all lung cancer cases.

The targeted anti-cancer drug erlotinib (Tarceva ®) has also demonstrated a small improvement in advanced pancreatic cancer survival when used in combination with gemcitabine.

Almost 72 % of docetaxel patients were current or former smokers, compared with 81.7 % in the erlotinib group.

A total of 28.9 % of patients receiving docetaxel had not progressed after 6 months, compared with 16.9 % of erlotinib patients.

For both populations, though, disease prognosis remains poor: the median progression - free survival for docetaxel - treated patients was 3.4 months, compared with 2.4 months for erlotinib.